Institute of environmental science and research - Abrocitinib Studied as Second-Line Biologic in Atopic Dermatitis

Abrocitinib shows consistent efficacy and safety in patients with moderate-to-severe atopic dermatitis, whether or not they've already been treated with a biologic, researchers...